This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
pnuC a NR/NMN transporter (most common; majority of Lactobacillales examples) nadA a Quinolate synthase (first committed step of de novo NAD⁺ biosynthesis; common in Planctomycetota) pncB a Nicotinate phosphoribosyltransferase (nicotinic acid salvage) ecf an ECF (energy-coupling factor) transporter cassette, likely involved in NAD⁺ homeostasis tsx a Nucleoside-specific channel
Gag-onc fusion protein Bcr-abl fusion protein Tpr-met fusion protein Antibodies are fusion proteins produced by V(D)J recombination. There are also rare examples of naturally occurring polypeptides that appear to be a fusion of two clearly defined modules, in which each module displays its characteristic activity or function, independent of the other. Two major examples are: double PP2C chimera in Plasmodium falciparum (the malaria parasite), in which each PP2C module exhibits protein phosphatase 2C enzymatic activity, and the dual-family immunophilins that occur in a number of unicellular organisms (such as protozoan parasites and Flavobacteria) and contain full-length cyclophilin and FKBP chaperone modules. The evolutionary origin of such chimera remains unclear.
In vertebrates, iron is an essential component of hemoglobin, the oxygen transport protein. A 2024 article reviewed iron metabolism and its interactions with calcium, magnesium, and selected trace elements (copper, zinc, lead, cadmium, mercury, and nickel), as well as their roles in certain diseases.
Sources: en.wikipedia.org
Greater Manchester Police confirm that, following their investigation, Labour deputy leader Angela Rayner will not face any further police action over her living arrangements before her time as an MP. Former Plaid Cymru MP Jonathan Edwards, who represents Carmarthen East and Dinefwr, announces he will not contest his seat at the election; Edwards was asked to leave Plaid in 2022 after accepting a police caution for assaulting his wife. Stormont passes the 2024 Northern Ireland budget, its first in three years, despite opposition from the Ulster Unionist Party, and the Assembly's official opposition, the Social Democratic and Labour Party. 29 May – MSPs vote 64–0 to exclude Scotland's former health secretary, Michael Matheson, from the Scottish Parliament for 27 sitting days, and to suspend his salary for 54 days, after he breached expenses rules by accumulating an £11,000 bill on his parliamentary iPad. The governing SNP abstains from voting, and calls for a review of the complaints procedure, suggesting it could be open to bias. The Welsh Conservatives table a motion of no confidence in First Minister Vaughan Gething following several weeks of controversy over donations to his leadership campaign. The motion is scheduled to face a Senedd vote on 5 June. Pat Cullen stands down as chief executive of the Royal College of Nursing in order to seek the nomination as Sinn Féin candidate for Fermanagh and South Tyrone in the general election.
However, when the pregnancy ends, the blood glucose levels return to normal in about 95 percent of all cases. It MUST be treated carefully by a physician for it is dangerous to both mother and child. If treated properly, there are usually no lasting effects on either. Women who have had an episode of GDM are at higher risk of developing Type 2 diabetes later on. Gingivitis infection of the gums, often chronic and low grade. Gland a tissue which produces a product used elsewhere. The pancreas is a large gland, and a complex one. It produces considerable quantities of bile acids for use in the intestines; these are carried to the intestines via ducts and so the pancreas is a ducted gland. Parts of the pancreas (chiefly the Islets of Langerhans) produce very small amounts of chemicals which are released directly into the blood; the pancreas is also therefore a ductless gland as well. These later substances are hormones, and so the pancreas is also an endocrine gland. Glaucoma an increase in the internal pressure in the eye. It is usually caused by a reduction in the outflow of fluid. Sufficiently high and prolonged glaucoma causes reduced vision by preventing perfusion of the retina, and can lead to blindness. Gliclazide A pill taken to lower the level of glucose (sugar) in the blood. Only some people with noninsulin-dependent diabetes take these pills. See also: Oral hypoglycemic agents. One of the sulfonylureas. (Diamicron) Glimepiride A pill taken to lower the level of glucose (sugar) in the blood. Only some people with noninsulin-dependent diabetes take these pills.
== Health considerations == Normal functioning of the kidney, brain, liver, heart, and numerous other systems can be affected by uranium exposure because uranium is a toxic metal, although less toxic than other heavy metals, such as arsenic and mercury. It is weakly radioactive and is 'persistently' so because of its very long half-life. The Agency for Toxic Substances and Disease Registry states that: "to be exposed to radiation from uranium, you have to eat, drink, or breathe it, or get it on your skin." If DU particles do enter an individual, the type of danger presented—toxic vs. radiological—and the organ most likely to be affected depend on the solubility of the particles. In military conflicts involving DU munitions, the major concern is inhalation of DU particles in aerosols arising from the impacts of DU-enhanced projectiles with their targets. When depleted uranium munitions penetrate armor or burn, they create depleted uranium oxides in the form of dust that can be inhaled or contaminate wounds. The Institute of Nuclear Technology-Radiation Protection of Attiki, Greece, has noted that "the aerosol produced during impact and combustion of depleted uranium munitions can potentially contaminate wide areas around the impact sites or can be inhaled by civilians and military personnel". The use of DU in incendiary ammunition is controversial because of potential adverse health effects and its release into the environment. The U.S. Department of Defense claims that no human cancer of any type has been seen as a result of exposure to either natural or depleted uranium.
== History == It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. On 4 July 2011, the European Medicines Agency (EMA) approved a paediatric investigation plan and granted both a deferral and a waiver for canagliflozin (EMEA-001030-PIP01-10) in accordance with EC Regulation No. 1901/2006 of the European Parliament and of the council. It was approved for medical use in the European Union in November 2013. Canagliflozin was approved by the FDA on 29 March 2013, and became the first SGLT2 inhibitor in the United States. Canagliflozin was approved for medical use in Australia in September 2013.
Sources: en.wikipedia.org
The College of Allied Health Sciences (CAHS) provides education for allied health and health science professionals. CAHS became a college at the University of Cincinnati in March 1998. Its programs originated from various colleges at the University of Cincinnati.
Glucose is an energy source in most life forms. For instance, polysaccharides are broken down into their monomers by enzymes (glycogen phosphorylase removes glucose residues from glycogen, a polysaccharide). Disaccharides like lactose or sucrose are cleaved into their two component monosaccharides.
Grow Papaver Somniferum from vizyonpara.com Comprehensive profile for Papaver somniferum from MaltaWildPlants.com Opium FAQ v1.0 from Opioids.com Opium Poppy Cultivation and Heroin Processing in Southeast Asia from the School of Pacific and Asian Studies "Downward Spiral – Banning Opium in Afghanistan and Burma", Transnational Institute TNI, Debate Paper, June 2005 "Withdrawal Symptoms in the Golden Triangle – A Drugs Market in Disarray" TNI Paper by Tom Kramer et al. Chouvy P.A., 2009, "Opium. Uncovering the Politics of the Poppy", London, I.B. Tauris (Cambridge, Harvard University Press: 2010)
== Research == Azacitidine can be used in vitro to remove methyl groups from DNA. This may weaken the effects of gene silencing mechanisms that occur prior to methylation. Certain methylations are believed to secure DNA in a silenced state, and therefore demethylation may reduce the stability of silencing signals and confer relative gene activation. Azacitidine induces tumor regression on isocitrate dehydrogenase-1 mutant glioma xenografts in mice. In research, 5-azacitidine is commonly used for promoting cardiomyocyte differentiation of adult stem cells. However, it has been suggested that this drug has a compromised efficacy as a cardiac differentiation factor because it promotes the transdifferentiation of cardiac cells to skeletal myocytes. Azacitidine also has antiviral effects in animal studies as well as its anti-cancer actions, but has not been tested for clinical use.
== Veterinary uses == Thiamazole is commonly used in cats to treat hyperthyroidism. Despite 20% of cats treated with thiamazole testing positive for antinuclear antibody lupus erythematosus and immune-mediated haemolytic anemia, neither condition is associated with thiamazole in cats. Hepatic toxicity also occurs in a small but notable amount of cats treated with thiamazole. In July 2024, the US Food and Drug Administration (FDA) approved Felanorm, the first generic methimazole oral solution for the treatment of hyperthyroidism in cats. Felanorm contains the same active ingredient (methimazole) as the approved brand name drug product, Felimazole Coated Tablets, which were first approved in May 2009. In addition, the FDA determined that Felanorm contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. Felanorm is sponsored by Norbrook Laboratories based in the United Kingdom.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.